Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Published in 2023 by
Patricia LoRusso,
Noboru Yamamoto,
Manish R. Patel,
Scott A. Laurie,
Todd M. Bauer 
,
Junxian Geng,
Teffany Davenport ,
Michael Teufel ,
Jian Li,
Mehdi Lahmar ,
Mrinal M. Gounder
,
Junxian Geng,
Teffany Davenport ,
Michael Teufel ,
Jian Li,
Mehdi Lahmar ,
Mrinal M. Gounder
